Welcome to our dedicated page for Autonomix Medical news (Ticker: $AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Autonomix Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Autonomix Medical's position in the market.
Rhea-AI Summary
Autonomix Medical, Inc. (AMIX) completes first three patient procedures for a PoC human clinical trial using transvascular RF ablation to reduce pancreatic cancer pain. The Company aims to ablate somatic nerves and alleviate pain in patients with pancreatic cancer, offering a promising alternative to current treatment methods. Enrollment for the trial is ongoing, with a focus on developing innovative technologies for pain management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.33%
Tags
-
Rhea-AI Summary
Autonomix Medical, Inc. (NASDAQ: AMIX) has initiated a groundbreaking human clinical trial to evaluate transvascular radiofrequency ablation for reducing pancreatic cancer pain. The trial aims to ablate somatic nerves to alleviate chronic pain, with enrollment expected to be completed by 2024. Autonomix plans to develop a catheter-based technology to sense and target nerves accurately, offering a more effective and precise treatment compared to current methods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
-
News
Rhea-AI Summary
Autonomix Medical, Inc. (NASDAQ: AMIX) announces the initiation of a proof-of-concept human clinical trial targeting the pancreatic cancer market through transvascular RF ablation. The company has signed agreements to commence patient enrollment soon, aiming to ablate somatic nerves and alleviate pain in patients with pancreatic cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.83%
Tags
Rhea-AI Summary
Autonomix Medical, Inc. (AMIX) announced a live webcast featuring CEO Lori Bisson discussing the company's innovative technologies for nervous system diseases. The event, scheduled for February 29th, will cover corporate overview, business outlook, and the Autonomix opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.2%
Tags
-
News
Rhea-AI Summary
Autonomix Medical, Inc. (AMIX) completes selection of Principal Investigators for a PoC human clinical trial targeting pancreatic cancer pain. The Company aims to revolutionize treatment through transvascular RF ablation, expecting to enroll 20 subjects by 2024. Autonomix plans to launch combined sensing/ablation clinical trial by 2025 and seek FDA clearance by 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
-
News
Rhea-AI Summary
Autonomix Medical, Inc. completes site initiation for a groundbreaking study on RF ablation for pancreatic cancer pain relief. The study aims to ablate somatic nerves to alleviate pain in patients with pancreatic cancer utilizing a transvascular approach. The Company is on track to commence patient enrollment this quarter and expects to complete enrollment by the end of 2024. Autonomix plans to launch a combined sensing/ablation clinical trial in 2025 and aims for FDA clearance by 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
Rhea-AI Summary
Autonomix Medical, Inc. (AMIX) reported financial results for Q3 FY2024, with recent highlights including an $11.2 million IPO, advancements in technology for pancreatic cancer pain treatment, and the formation of an engineering development team. The Company aims to revolutionize nervous system disease treatment and is on track to start a groundbreaking study on radiofrequency ablation for pancreatic cancer pain in Q1 CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.15%
Tags
-
Rhea-AI Summary
Autonomix Medical, Inc. (AMIX) will present at Integrous Communications' Big Hearts, Big Ideas Virtual Investor Conference on February 14, 2024. The company focuses on innovative technologies for nervous system diseases. CEO Lori Bisson will lead the presentation, with opportunities for one-on-one meetings. The webcast will be available on the conference website and Autonomix's Events page for a year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
-
Rhea-AI Summary
Autonomix Medical, Inc. (NASDAQ: AMIX) has received authorization to open a clinical trial site in Uzbekistan for a human clinical study evaluating the use of transvascular ablation for the treatment of pancreatic cancer pain. The company is on track to commence enrollment in the first quarter of 2024. The primary objective of the study is to ablate relevant somatic nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region. The company's catheter-based sensing technology is being developed to sense neural signals associated with pain or disease and precisely target those nerves for treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
News
Rhea-AI Summary
Autonomix Medical, Inc. (NASDAQ: AMIX) will present at the Virtual Investor New to the Street Event on February 7, 2024. The company's management team will provide a corporate overview and business outlook, with an opportunity for live questions from investors. The event will be available for live webcast and replay on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Autonomix Medical, Inc.
Nasdaq:AMIX
AMIX Rankings
AMIX Stock Data
38.75M
8.65M
46.2%
0.02%
0.19%
Medical Devices
Healthcare
United States of America
THE WOODLANDS